Convalescent Plasma in Older Adults with COVID-19: A Systematic Review and Meta-Analysis
Annals of Geriatric Medicine and Research · 2022-09-30 · 26 (3) · 208-214
DOI: 10.4235/agmr.22.0045 ↗Abstract
Background: Among all patients infected with coronavirus disease 2019 (COVID-19), the older adult population was the most affected, with 80%–90% of fatalities occurring in this group. The effectiveness of convalescent plasma (CP) in older adults is considerably more restricted than that in adults, resulting in a demand for data on the efficacy of therapeutic CP in older adults. This meta-analysis of updated literature examined the effect of CP in older adults with COVID-19.Methods: Relevant literature was identified from studies indexed in the Cochrane, PubMed, and Google Scholar databases between December 2019 and April 2022. The primary outcome was all-cause mortality. Risk estimates were pooled using a random-effects model. The risk of bias was assessed by regression-based Egger test using the relative risk (RR) and upper and lower confidence intervals (CIs) of the three included studies.Results: Among 377 studies identified, three full-text studies that included 1,038 patients met the inclusion criteria. The results of our meta-analysis showed that CP administration lowered the mortality risk in older adults with COVID-19 (RR=0.47; 95% CI, 0.26–0.86; p=0.01; I2=0%, p
EUVIMED